Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis
<p><strong>Introduction: </strong>Bortezomib is a proteasome inhibitor that targets myeloma cell and its bone marrow micro-environment. Intravenous Bortezomib (1.3 mg/m<sup>2</sup> administered on days 1,4,8 and 11 of a 21 day cyc...
| 發表在: | Mediterranean Journal of Hematology and Infectious Diseases |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Article |
| 語言: | 英语 |
| 出版: |
PAGEPress Publications
2012-01-01
|
| 主題: | |
| 在線閱讀: | http://www.mjhid.org/article/view/10316 |